Money Flowing Into Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN is having a nice session on Tuesday, climbing 4% to $55.19. Volume has been rather anemic, however. Last week, an FDA panel recommended that the agency approve Regeneron's eye drug, VEGF Trap-Eye. The company currently has a market cap of $5.02 billion. The median Wall Street price target on REGN is $62.50 with a high target of $56.00. Regeneron Pharmaceuticals, Inc. (Regeneron) is a biopharmaceutical company. Regeneron discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions.